{Reference Type}: Journal Article
{Title}: Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: A systematic review.
{Author}: Smith ECC;Au E;Pereira S;Sharma E;Venkatasubramanian G;Remington G;Agarwal SM;Hahn M;
{Journal}: Psychiatry Res
{Volume}: 328
{Issue}: 0
{Year}: 2023 Oct 7
{Factor}: 11.225
{DOI}: 10.1016/j.psychres.2023.115472
{Abstract}: Antipsychotics (APs) are the cornerstone of treatment for schizophrenia (SCZ) spectrum disorders. Previous research suggests that there may be a positive association between AP-induced weight gain and/or dyslipidemia and improvement in psychiatric symptoms, often referred to as a "metabolic threshold". To determine whether a similar relationship exists for glucose parameters, we conducted a systematic search in six databases from inception to June 2022 for all longitudinal studies that directly examined the relationship between changes in glucose-related outcomes and changes in psychopathology among patients with SCZ treated with APs. We identified 10 relevant studies and one additional study that considered cognition. In most cases, we found that increased levels of fasting glucose and insulin following treatment were associated with clinical improvement. These findings contribute to existing literature that could suggest a common mechanism between AP action and metabolic side effects and support a need for additional work aimed at exploring the validity of a glucose-psychopathology relation in SCZ.